Climb Bio, Inc.'s SEC filings document a Nasdaq-listed clinical-stage biotechnology company developing therapeutics for immune-mediated diseases. The filings cover operating and financial results, Regulation FD pipeline disclosures, material-event reports and capital-structure information for common stock listed under the symbol CLYM.
Company filings also describe budoprutug and CLYM116 development disclosures, financing arrangements, executive and accounting officer changes, and governance matters presented in proxy materials. Proxy disclosures address director elections, auditor ratification, charter amendments, equity incentive plan provisions, stockholder voting procedures and other annual meeting matters.
Climb Bio, Inc. is a clinical-stage biotech developing budoprutug and CLYM116 for immune‑mediated diseases. For the quarter ended June 30, 2026 it reported a net loss of $13.5 million, wider than $8.7 million a year earlier, driven mainly by higher research and development and general and administrative expenses.
For the first six months of 2026, the net loss was $27.2 million versus $29.4 million in 2025 as prior‑year spending included a $9.0 million upfront CLYM116 license payment. Cash, cash equivalents and marketable securities totaled $239.2 million, including $103.4 million of net proceeds from an April 2026 private placement, which the company expects will fund operations into the second half of 2028.
The pipeline advanced with ongoing Phase 2 development of budoprutug in primary membranous nephropathy, Phase 1b/2a trials in immune thrombocytopenia and systemic lupus erythematosus, and a subcutaneous formulation showing robust B‑cell depletion in Phase 1. CLYM116 completed Phase 1 dosing in healthy volunteers, with pharmacokinetic and pharmacodynamic data expected in late 2026, while multiple partnered and in‑licensed programs carry substantial future milestone and royalty obligations.
Climb Bio, Inc. reported results for the quarter ended June 30, 2026 and highlighted progress across its budoprutug and CLYM116 programs. For CLYM116, the company plans an R&D Spotlight on September 3, 2026 to review initial Phase 1 PK/PD data in healthy volunteers and development plans in IgA nephropathy, and anticipates initiating dosing in a Phase 2 IgA nephropathy trial in the third quarter of 2026. A partner-led Phase 1/2 study in IgA nephropathy in China is also ongoing, with Phase 2 dosing expected to begin in the third quarter of 2026.
For budoprutug, enrollment continues in the global PrisMN Phase 2 trial in primary membranous nephropathy, with initial pharmacodynamic data from the low-dose cohort expected in the fourth quarter of 2026. Additional data in immune thrombocytopenia, systemic lupus erythematosus and from a subcutaneous formulation study are expected through late 2026 and 2027. The company completed a private placement on April 29, 2026 generating approximately $110 million in gross proceeds, supporting continued clinical advancement and extending its cash runway into the second half of 2028. Cash, cash equivalents and marketable securities totaled $239.2 million as of June 30, 2026. For the quarter, R&D expenses were $9.7 million, G&A expenses were $5.6 million, and other income, net was $1.9 million; the company reported a net loss for the period.
FMR LLC reports beneficial ownership of 6,790,364 shares of CLIMB BIO INC common stock, representing 11.9% of the class as of 06/30/2026. The filing (Schedule 13G) states FMR LLC holds sole dispositive power over these shares and identifies Abigail P. Johnson as having dispositive power. The report lists the issuer CUSIP 28658R106 and provides FMR's principal office in Boston.
RA Capital Management and affiliates updated their ownership disclosure in Climb Bio, Inc., reporting a sizable stake and a board change. The reporting group beneficially owns 23,249,186 shares of common stock, representing 33.0% of the company, including shares underlying pre-funded warrants and stock options exercisable within 60 days.
The filing explains that RA Capital advises multiple funds and accounts that hold Climb Bio securities and has delegated voting and investment power over those positions. A "Beneficial Ownership Blocker" in the pre-funded warrants limits exercises so the group cannot exceed 33.0% ownership. The amendment also notes that on June 29, 2026, RA Capital analyst Dr. Breanna Celebi was appointed to Climb Bio’s board of directors as RA Capital’s designee, replacing Dr. Andrew Levin, who resigned the same day. Additionally, on July 2, 2026, Sera Medicines made a pro rata in-kind distribution of 2,479,872 Climb Bio shares to its members, with RA Capital funds receiving portions of those shares.
Climb Bio, Inc. reported a Form 4 showing a grant of stock options tied to 70,284 shares of common stock at an exercise price of $13.36 per share. The options vest in equal monthly installments from June 29, 2026 over three years and expire on June 29, 2036. The options are held by Ms. Celebi for the benefit of several RA Capital funds and an account, and any net cash or stock received upon exercise must be turned over to RA Capital Management, offsetting advisory fees. The reporting persons disclaim beneficial ownership of the option and underlying shares except to the extent of any pecuniary interest.
Climb Bio, Inc. director Breanna Maurine Celebi was granted a stock option covering 70,284 shares of common stock at an exercise price of $13.36 per share. The option vests in equal monthly installments starting on June 29, 2026 and continuing until the third anniversary of that date, contingent on continued service. Under an arrangement with RA Capital Management, L.P., any net cash or stock from exercising this option must be turned over to RA Capital-managed funds and an account to offset advisory fees, and the reporting person therefore disclaims beneficial ownership of the option and its underlying shares.
Climb Bio, Inc. director Breanna Maurine Celebi has filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. This filing lists her as a director of the company but does not report any share transactions or existing holdings at this time.
Climb Bio, Inc. reported that director Andrew Levin resigned from its board, effective June 29, 2026. On the same day, the board elected Breanna O’Reilly, Ph.D., as a new director, with a term running until the 2027 annual meeting and until a successor is in place.
As a non-employee director, Dr. O’Reilly received a stock option to purchase 70,284 shares at an exercise price of $13.36 per share, vesting in equal monthly installments over three years from June 29, 2026. She will also receive a $40,000 annual cash retainer and ongoing annual equity grants under the company’s non-employee director compensation policy, and is covered by an indemnification agreement for certain expenses related to her board service.
Climb Bio, Inc. President and CEO Aoife Brennan exercised restricted stock units and sold shares in a planned transaction. On June 27, 2026, 68,750 RSUs converted into the same number of common shares as part of a four-year vesting grant. On June 29, 2026, Brennan sold 30,902 common shares at a weighted average price of $13.17 per share pursuant to a Rule 10b5-1 trading plan to cover tax withholding obligations tied to the RSU vesting. After these transactions, Brennan directly owned 87,731 common shares, including 1,751 acquired through the employee stock purchase plan, and continued to hold RSUs scheduled to vest annually over four years.